MyoKardia Inc. (MYOK) Sees Strong Trading Volume
MyoKardia Inc. (NASDAQ:MYOK) shares saw unusually-high trading volume on Wednesday . Approximately 169,808 shares were traded during mid-day trading, an increase of 76% from the previous session’s volume of 96,591 shares.The stock last traded at $21.88 and had previously closed at $21.96.
MYOK has been the topic of several recent analyst reports. Cowen and Company reissued a “buy” rating on shares of MyoKardia in a report on Friday, May 13th. Credit Suisse Group AG reissued a “buy” rating and issued a $20.00 target price (up from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. Zacks Investment Research raised MyoKardia from a “sell” rating to a “hold” rating in a report on Tuesday, August 23rd. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of MyoKardia in a research report on Thursday, May 12th. Finally, BMO Capital Markets initiated coverage on shares of MyoKardia in a research report on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.50.
The company’s market capitalization is $591.20 million. The firm has a 50-day moving average of $18.34 and a 200-day moving average of $13.09.
MyoKardia (NASDAQ:MYOK) last issued its earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $3.55 million for the quarter, compared to analysts’ expectations of $3.55 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities analysts expect that MyoKardia Inc. will post ($1.50) earnings per share for the current fiscal year.
MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.